'Pharma Bro' Martin Shkreli is in trouble with regulators again, this time for influencing biopharma stocks

The Federal Trade Commission and seven states say Shkreli should be held in contempt Martin Shkreli was found guilty in 2017 of two counts of securities fraud and one count of…

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.morningstar.com)